Xu, Dongxiao,
Gareev, Ilgiz,
Beylerli, Ozal,
Pavlov, Valentin,
Le, Huang,
Shi, Huaizhang (2024) to withstand SAH, succumbing to adverse
outcomes despite intensive therapeutic interventions, even in premier
Bovell-Ammon, B.J.,
Kimmel, S.D.,
Cheng, D.M.,
Truong, V.,
Michals, A.,
Vetrova, M.,
Hook, K.,
Idrisov, B.,
Blokhina, E.,
Krupitsky, E.,
Samet, J.H.,
Lunze, K. (2023) incarceration and two secondary
outcomes: HIV stigma score (11-item abbreviated Berger scale) and substance use
Motloch, LJ;,
Jirak, P;,
Gareeva, D;,
Davtyan, P;,
Gumerov, R;,
Lakman, I;,
Tataurov, A;,
Zulkarneev, R;,
Kabirov, I;,
Cai, BZ;,
Valeev, B;,
Pavlov, V;,
Kopp, K;,
Hoppe, UC;,
Lichtenauer, M;,
Fiedler, L;,
Pistulli, R;,
Zagidullin, N (2022) of cardiovascular biomarkers on predicting
outcomes in COVID-19 patients is still unknown. Therefore, to investigate
complex pathophysiology and improving patient
outcomes. This novel approach not only promises to mitigate